Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.